|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Heterogeneous nuclear ribonucleoprotein A2B1 (HNRNPA2B1) is closely related to tumour occurrence and development, oncogene expression, apoptosis inhibition and invasion and metastasis capacities.
|
28077929 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We knocked down HNRNPA2B1 using small hairpin RNAs and measured viability, anchorage-independent proliferation, and growth of xenograft tumors in mice.
|
24998203 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Knockdown of hnRNP A2/B1 in glioblastoma cells inhibited tumor formation in mice.
|
21586613 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Comparison between tumor probes and tumor-free specimens of NSCLC patients failed to approve the diagnostic relevance of hnRNP A2/B1 shown in previous studies, whereas hnRNP B1 revealed a high tumor specificity that could be helpful for tumor cell screening.
|
17067748 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
hnRNP-A2/B1 affected tumor cell differentiation through interaction with oncogenes and tumor-suppressor genes, and it was overexpressed in human gastric cancer.
|
21175803 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The growth of nude mouse xenograft tumor was significantly reduced by hnRNP A2/B1 knock‑down.
|
29328485 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, our results demonstrate that hnRNPA2/B1 promotes tumor cell growth by activating COX-2 signaling in NSCLC cells and imply that the hnRNPA2/B1/COX-2 pathway may be a potential therapeutic target for human lung cancers.
|
26774881 |
2016 |
|
Cataract
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Alkaline phosphatase raised
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Proximal muscle weakness
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Waddling gait
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Abnormal behavior
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Cerebral atrophy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Creatine phosphokinase serum increased
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4.
|
8631886 |
1996 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our results demonstrate that hnRNPA2/B1 promotes tumor cell growth by activating COX-2 signaling in NSCLC cells and imply that the hnRNPA2/B1/COX-2 pathway may be a potential therapeutic target for human lung cancers.
|
26774881 |
2016 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer.
|
25483567 |
2015 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
ECH1 and HNRNPA2B1 are autoantigens that elicit autoimmune responses in LC and their autoantibody can be the potential biomarkers for the early detection of LC.
|
28638733 |
2017 |
|
Muscle fiber atrophy
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Short stature
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Distal muscle weakness
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Cranial nerve compression
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Skeletal muscle atrophy
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
hnRNP A2/B1 has been suggested as a useful early detection marker for lung carcinoma. hnRNP A2/B1 is a member of a large family of heterogeneous nuclear ribonucleoproteins (hnRNP proteins) involved in a variety of functions, including regulation of transcription, mRNA metabolism, and translation.
|
12871776 |
2003 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer.
|
25483567 |
2015 |